Literature DB >> 214028

Antiviral activity of intranasally applied human leukocyte interferon.

S B Greenberg, M W Harmon, P E Johnson, R B Couch.   

Abstract

Previous studies in our laboratory have demonstrated that the development of antiviral activity of human leukocyte interferon (IF) in nasal epithelial cells is time and concentration dependent and that the loss of intranasally applied human leukocyte IF is rapid. The present studies compared the activity of IF applied intranasally either by nasal drops or by a saturated cotton pledget. Adult volunteers had IF applied to an area of nasal mucosa (2 by 2 cm(2)) either by repeated nose drops or by a saturated cotton pledget that was applied to the nasal mucosa and left in place for 1 h. Nasal epithelial cells scraped from the area of application, as well as the control, untreated side of the same volunteers, were challenged with vesicular stomatitis virus. No significant reduction in mean virus yield was found in volunteers who received 80,000 U by nose drops. Significant reduction (P < 0.025) in mean virus yield was found in cells obtained 4 h after 80,000, 50,000, or 20,000 U was applied by cotton pledget or in volunteers pretreated with oral antihistamines prior to receiving 80,000 U by nose drops. These experiments indicate that nasal epithelial cells can be made antiviral in vivo by application of human leukocyte IF. However, practical usefulness of human leukocyte IF for prophylaxis against respiratory viral infections may depend on the method of local application.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 214028      PMCID: PMC352512          DOI: 10.1128/AAC.14.4.596

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  The reduction in vitro in viscosity of mucoprotein solutions by a new mucolytic agent, N-acetyl-L-cysteine.

Authors:  A L SHEFFNER
Journal:  Ann N Y Acad Sci       Date:  1963-03-30       Impact factor: 5.691

2.  Serologic response of incividuals infected with para influenza viruses.

Authors:  R M CHANOCK; D C WONG; R J HUEBNER; J A BELL
Journal:  Am J Public Health Nations Health       Date:  1960-12

3.  Effect of human nasal secretions on the antiviral activity of human fibroblast and leukocyte interferon.

Authors:  M W Harmon; S B Greenberg; R B Couch
Journal:  Proc Soc Exp Biol Med       Date:  1976-09

4.  Distribution and removal of human serum albumin-technetium 99m instilled intranasally.

Authors:  F Y Aoki; J C Crowley
Journal:  Br J Clin Pharmacol       Date:  1976-10       Impact factor: 4.335

5.  Inhibition of respiratory virus infection by locally applied interferon.

Authors:  T C Merigan; S E Reed; T S Hall; D A Tyrrell
Journal:  Lancet       Date:  1973-03-17       Impact factor: 79.321

Review 6.  The upper airways. I. Nasal physiology and defense of the lungs.

Authors:  D F Proctor
Journal:  Am Rev Respir Dis       Date:  1977-01

Review 7.  Human leukocyte interferon: production, purification, stability, and animal experiments.

Authors:  K Cantell; S Hirvonen; K E Mogensen; L Pyhälä
Journal:  In Vitro Monogr       Date:  1974

8.  Activity of exogenous interferon in the human nasal mucosa.

Authors:  S B Greenberg; M W Harmon; P E Johnson
Journal:  Tex Rep Biol Med       Date:  1977

9.  Human nasal epithelial cell culture system: evaluation of response to human interferons.

Authors:  M W Harmon; S B Greenberg; P E Johnson; R B Couch
Journal:  Infect Immun       Date:  1977-05       Impact factor: 3.441

10.  Recovery of applied human leukocyte interferon from the nasal mucosa of chimpanzees and humans.

Authors:  P E Johnson; S B Greenberg; M W Harmon; B R Alford; R B Couch
Journal:  J Clin Microbiol       Date:  1976-07       Impact factor: 5.948

View more
  12 in total

Review 1.  Interferon: therapeutic fact or fiction for the '80s?

Authors:  G M Scott; D A Tyrrell
Journal:  Br Med J       Date:  1980-06-28

2.  Failure of human fibroblast interferon to protect against rhinovirus infection.

Authors:  G M Scott; S Reed; T Cartwright; D Tyrrell
Journal:  Arch Virol       Date:  1980       Impact factor: 2.574

3.  Intranasal interferon-alpha 2 for prevention of natural rhinovirus colds.

Authors:  B M Farr; J M Gwaltney; K F Adams; F G Hayden
Journal:  Antimicrob Agents Chemother       Date:  1984-07       Impact factor: 5.191

Review 4.  Interferons and interferon inducers: development of clinical usefulness and therapeutic promise.

Authors:  R B Pollard
Journal:  Drugs       Date:  1982 Jan-Feb       Impact factor: 9.546

5.  Purified interferon as protection against rhinovirus infection.

Authors:  G M Scott; R J Phillpotts; J Wallace; D S Secher; K Cantell; D A Tyrrell
Journal:  Br Med J (Clin Res Ed)       Date:  1982-06-19

6.  Duration of effect of interferon aerosol prophylaxis of vesicular stomatitis virus infection in mice.

Authors:  P R Wyde; C S Sun; S Z Wilson; V Knight
Journal:  Antimicrob Agents Chemother       Date:  1985-01       Impact factor: 5.191

7.  Interferon aerosol suppression of vesicular stomatitis virus replication in the lungs of infected mice.

Authors:  P R Wyde; S Z Wilson; C S Sun; V Knight
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

8.  Pulmonary deposition and clearance of aerosolized interferon.

Authors:  P R Wyde; S Z Wilson; M J Kramer; C S Sun; V Knight
Journal:  Antimicrob Agents Chemother       Date:  1984-06       Impact factor: 5.191

9.  A study of intranasally administered interferon A (rIFN-alpha 2A) for the seasonal prophylaxis of natural viral infections of the upper respiratory tract in healthy volunteers.

Authors:  G A Tannock; S M Gillett; R S Gillett; R D Barry; M J Hensley; R Herd; A L Reid; N A Saunders
Journal:  Epidemiol Infect       Date:  1988-12       Impact factor: 2.451

Review 10.  Antiviral chemotherapy and prophylaxis of viral respiratory disease.

Authors:  S J Sperber; F G Hayden
Journal:  Clin Lab Med       Date:  1987-12       Impact factor: 1.935

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.